5-[(5-methyl-3-{3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1H-1,2,4-triazol-1-yl)methyl]-1-(2-methylpropyl)-1,2-dihydropyridin-2-one | 1570496-18-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-[(5-methyl-3-{3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1H-1,2,4-triazol-1-yl)methyl]-1-(2-methylpropyl)-1,2-dihydropyridin-2-one
• 英文别名: 1-(2-Methylpropyl)-5-[[5-methyl-3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]-1,2,4-triazol-1-yl]methyl]pyridin-2-one；1-(2-methylpropyl)-5-[[5-methyl-3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]-1,2,4-triazol-1-yl]methyl]pyridin-2-one
• CAS: 1570496-18-2
• 化学式: C₂₂H₂₁F₃N₆O₃
• 分子量: 474.442
• InChiKey: RMBMFCJNTRTLNY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  99.2
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  溴代异丁烷 、 5-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-1,2,4-triazol-1-yl)methyl)pyridin-2(1H)-one 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 5-[(5-methyl-3-{3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1H-1,2,4-triazol-1-yl)methyl]-1-(2-methylpropyl)-1,2-dihydropyridin-2-one 、 5-(1-((6-isobutoxypyridin-3-yl)methyl)-5-methyl-1H-1,2,4-triazol-3-yl)-3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole
  参考文献：
  名称：

  [EN] HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
  [FR] MODULATEURS HÉTÉROCYCLIQUES DE L'ACTIVITÉ DU FACTEUR HIF UTILISÉS POUR LE TRAITEMENT DE MALADIES

  摘要：

  公开号：

  WO2014031936A3

文献信息

• Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
  申请人：Jones Robert M.

  公开号：US20140066369A1

  公开（公告）日：2014-03-06

  The present invention relates to compounds of Formula I and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as single pharmaceutical agents or in combination with one or more additional pharmaceutical agents, such as, a DPP-IV inhibitor, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.

  本发明涉及式I化合物及其药学上可接受的盐、溶剂和水合物，它们可作为单一药物或与一个或多个其他药物联合使用，例如DPP-IV抑制剂、双胍类药物、α-葡萄糖苷酶抑制剂、胰岛素类似物、磺脲类药物、SGLT2抑制剂、噻唑烷二酮类药物或抗糖尿病肽类似物，用于治疗选择性疾病，例如GPR119受体相关疾病、通过增加血液肠促素水平改善的病症、低骨量的病症、神经系统疾病、代谢相关疾病、2型糖尿病、肥胖及其相关并发症。
• HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
  申请人：Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center

  公开号：US20140066424A1

  公开（公告）日：2014-03-06

  The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.

  本发明涉及化合物和方法，可用作HIF通路活性的抑制剂，用于治疗或预防癌症和其他缺氧介导的疾病。
• Heterocyclic modulators of HIF activity for treatment of disease
  申请人：Board of Regents, University of Texas System

  公开号：US10208059B2

  公开（公告）日：2019-02-19

  The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.

  本发明涉及可作为 HIF 通路活性抑制剂用于治疗或预防癌症和其他缺氧介导的疾病的化合物和方法。
• US9018380B2
  申请人：——

  公开号：US9018380B2

  公开（公告）日：2015-04-28